The Cautionary Tale
What the warnings actually did: a decade of Melanotan II enforcement
The gray-market article ends on a sentence that is true and incomplete: health agencies issued warnings and moved to block sales; the warnings documented the problem; they did not end the market. This is the follow-up. Not another warning. A file of what enforcement actually tried — website takedowns, listing removals, border seizures, a paid Australian fine, one American felony — and why a product that is approved nowhere is still for sale in daylight.
The pattern is the same in every jurisdiction that has bothered to act. Regulators can raise the cost of being a named seller. They cannot invent the missing approved drug, and they cannot police a molecule that keeps changing costume.
The 2010s playbook worked on websites
In 2014, a UK health minister told Parliament what the Medicines and Healthcare products Regulatory Agency had been doing about Melanotan. In the previous twelve months the agency had worked with internet service providers, in Britain and abroad, to suspend more than a hundred websites illegally trading in it. As of 12 June that year the MHRA had 22 reports of suspected adverse reactions, describing 93 events. The product was being sold through gyms and beauty salons as well as the internet. No Melanotan product held a UK licence. Sale or supply was a breach.
That is what a medicines regulator does when the thing in front of it is unambiguously a medicine: take down the shopfront. Ireland’s Health Products Regulatory Authority ran the same play a decade later, at social-media scale. On 10 August 2023 it said Melanotan 2 was not authorised by the HPRA or any medicines regulator to treat any condition, was not a cosmetic, and had no known legitimate suppliers. Between July 2022 and June 2023 it removed more than 500 social-media and e-commerce listings — more in twelve months than in the two years before that combined. It said it would prosecute where the public-health risk was significant.
The listings came down. The molecule did not. A takedown is a URL. The next URL is free.
Then the product stopped being a medicine
The influencer-era piece is the mechanism. Nasal sprays and flavoured drops restyled an injectable as a beauty product. In the UK that was not only marketing. It was a jurisdictional event.
On 1 December 2025, answering a written question about who is responsible for keeping tan-enhancing Melanotan II products off the market, the Department of Health and Social Care put the split on the record. Injectable products containing Melanotan I or Melanotan II are medicinal, the minister said, because of their similarity to the authorised medicine Scenesse. Nasal sprays, in the absence of medicinal claims, “are not regarded as medicinal products.” They are therefore not in the MHRA’s remit.
That sentence is the whole of the 2020s enforcement problem in the United Kingdom. The 2014 website-takedown machine still exists. It no longer points at the product people actually buy. Trading Standards and journalists have been filling the hole the medicines agency was told it does not own: BBC reporters bought sprays over the counter in Manchester, Merseyside, and a Newcastle gym in 2025; an S4C undercover team in Wales in June 2026 paid cash for an unlabelled bottle from a salon that volunteered, while selling it, that “they’re illegal.” Another seller, asked what was in the bottle, said she hadn’t got a clue.
Enforcement that cannot decide whether the object is a medicine, a cosmetic, or a general consumer product will always arrive after the sale.
Australia fined a person. Then it tested the bottle.
Australia is the jurisdiction that went furthest past the press release.
In January 2025 the Therapeutic Goods Administration told the public it was illegal to supply melanotan tanning products without a prescription, in any form — spray, tablet, injection, cream — and illegal to advertise them, including through social-media influencers. In 2023–24 the TGA asked platforms to take down more than 4,800 unlawful advertisements for therapeutic goods; many were from the wellness and beauty trade. That is the warning layer. The next layer had a name and an amount.
On 21 May 2026 the TGA issued 27 infringement notices, totalling $101,412, to a New South Wales individual for the alleged unlawful supply of Melanotan II. The notices were paid that month. There are no Melanotan II products on the Australian Register of Therapeutic Goods.
In August the same investigation produced the number this file has been waiting for. The TGA seized nasal-spray bottles labelled “Pure Tans Triple Strength 30 MG.” Laboratory testing of five of them, based on the labelled volume of 20 mL, put the Melanotan II content between 22 mg and 54 mg. The label was not a specification. It was a suggestion. That is the vial problem, measured, on a regulator’s letterhead.
In February 2026, as the regulatory tracker records, Australia had already done what no other country has: moved Melanotan II to Schedule 9, the prohibited list, so that possession without a research licence is itself a criminal offence. The fine, the lab result, and the scheduling decision are the same story at three resolutions. Raise the cost of selling. Prove the label is fiction. Then criminalise holding the bottle.
The bottles are still there. The August advisory exists because the TGA was still seizing them six months after Schedule 9.
What a border actually sees
Norway publishes the unglamorous version. Melanotan is not an approved medicine and is illegal to import. Customs does not issue lifestyle warnings; it opens parcels. In May 2025 the Norwegian Customs Service said that from 2023 to that date it had stopped nearly 2,500 units — most of them small postal consignments, most of those destroyed rather than prosecuted. In March it had taken 110 nasal-spray bottles off a single stop at Svinesund, the Swedish border. Larger quantities get referred to police. The small ones mostly vanish into an incinerator.
That is what resilient supply looks like as data. Not a cartel warehouse. A postbag, over and over, below the threshold at which a prosecutor’s time is worth more than the powder.
In January 2026 Norway’s medicines agency, DMP, ordered a domestic site to stop advertising melanotan and retatrutide in every channel it controlled. Advertising is legal in Norway only for products that hold a marketing authorisation. Neither does. The site took the pages down after the warning. The parcels, on the agency’s own account, keep arriving.
The United States named a company. Then the companies stopped having names.
American enforcement has one complete arc, and it is old.
In August 2007 the FDA sent a warning letter to Melanocorp, a Tennessee firm selling Melanotan II as an injectable tanning product, with claims about skin cancer and rosacea, advertised as “100% U.S. made.” Some of it was coming from China. Melanocorp wrote back that it had stopped selling to U.S. addresses. The FDA wrote again: unapproved new drugs do not qualify for export either. Melanocorp kept shipping — mostly abroad, some still domestic. In 2015 its president, Edward Manookian, pleaded guilty to two counts of conspiracy against the United States. Judgment went down that August. In 2016 the FDA moved to debar him for life from the regulated drug business.
That is as far as the named-company model goes. A warning letter, a false compliance letter, continued commerce, a felony, a debarment. After that the market learned the lesson Melanocorp was slow to learn: do not be a company the FDA can address. Be a listing, a drop-shipper, a “research chemical” page, a salon drawer. The 2020 warning letter to Tailor Made Compounding still had to list Melanotan II among bulk substances a pharmacy was not allowed to compound. The compounding door, as the three-doors primer maps, stayed shut. The gray-market door never needed a compounding pharmacy.
Why this keeps losing
Four structural facts, none of them secret:
The buyer is usually not the crime. In the UK it is illegal to sell Melanotan II as a medicine and legal to possess it. Ireland and the United States police supply, not the person who used it. Only Australia has made holding the bottle the offence. Demand that is not a crime does not dry up because a URL died.
The form keeps slipping the statute. An injectable looks like Scenesse, so it is a medicine. A spray with no medical claim, in British law as of December 2025, does not. Cosmetics law does not cover it either. Trading Standards inherits a product nobody’s rulebook was written to test. The gap is not a loophole a clever lawyer found. It is two statutes failing to meet.
Listings and parcels are cheaper to replace than to police. Ireland’s 500 takedowns in a year, Britain’s hundred websites in 2014, Norway’s thousands of destroyed units, Australia’s 4,800 advertising takedown requests — those are real costs imposed on this week’s sellers. They are not a barrier to entry. The next shopfront is a new account.
There is still no approved substitute for the general public. That is the sentence the warning articles never reach and the one this site will not drop. Enforcement is what a regulator does about an unapproved product. It is not what a medicines system does about an unmet indication. Afamelanotide exists, for a rare disease, as an implant. The original photoprotective brief — a tested agonist for ordinary skin — does not. A market formed in that vacancy in the 2000s. Taking down its websites does not close the vacancy.
The mole problem is still the mole problem. Nobody knows what’s in the vial — and now a national laboratory has said so in milligrams. The regulatory tracker will keep the dates. None of that is the same as ending the market, and pretending otherwise is how the last decade of warnings spent itself.
A legitimate, tested photoprotective agonist would do what the seizures cannot. That remains the open question, and it is labeled as one. The middle-ground agonist is the file on that. This one is the file on everything that was tried instead.